Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study

Shou-Sheng Chu,Yu-Hsuan Kuo,Wen-Shan Liu,Shih-Chang Wang,Chung-Han Ho,Yi-Chen Chen,Ching-Chieh Yang,Hung-Chang Wu
DOI: https://doi.org/10.1038/s41598-021-81176-w
IF: 4.6
2021-01-15
Scientific Reports
Abstract:Abstract Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) patients. This study aims to determine whether combining radiotherapy with sorafenib administration increases its efficacy. The study cohort included 4763 patients with diagnosed advanced HCC who received sorafenib between January 2012 and December 2015, as reported in medical records in the Taiwan Cancer Registry database. The effect of sorafenib with or without radiotherapy on survival was calculated using the Kaplan–Meier method and compared using the log-rank test. A Cox proportional hazards model was used for multivariate analysis. Patients receiving sorafenib plus radiotherapy had greater 1-year survival than did those receiving sorafenib alone ( P < 0.001). Uni- and multivariate analyses also showed that radiotherapy increased survival after adjusting for confounders (adjusted HR 0.57; 95% CI 0.51–0.63). Further stratified analysis according to the timing of radiotherapy relative to sorafenib treatment revealed that patients who underwent radiotherapy after sorafenib had greater 1-year survival than did those undergoing radiotherapy within sorafenib use or sorafenib alone (adjusted HR 0.39; 95% CI 0.27–0.54). Combined treatment with sorafenib and radiotherapy results in greater HCC patient survival and should be considered an option for treating this challenging disease.
multidisciplinary sciences
What problem does this paper attempt to address?
This paper aims to explore the impact of the combined use of radiotherapy and sorafenib on the survival rate of patients with advanced hepatocellular carcinoma (HCC). Specifically, researchers hope to determine whether adding radiotherapy can improve the survival rate of patients on the basis of sorafenib, a standard treatment drug. The study compared the survival situations of advanced HCC patients who only received sorafenib treatment with those who received both sorafenib and radiotherapy by analyzing the data in the Taiwan Cancer Registry Database. The research results show that the 1 - year survival rate of patients receiving sorafenib plus radiotherapy is significantly higher than that of patients only receiving sorafenib treatment (P < 0.001). Multivariate analysis also confirms that after adjusting for confounding factors, radiotherapy can increase the survival rate of patients (adjusted hazard ratio [aHR] 0.57; 95% confidence interval [CI] 0.51 - 0.63). In addition, further stratified analysis shows that the 1 - year survival rate of patients who receive radiotherapy after sorafenib treatment is the highest (adjusted hazard ratio [aHR] 0.39; 95% CI 0.27 - 0.54), which is better than that of patients during sorafenib treatment or only receiving sorafenib treatment. In conclusion, this study provides evidence to support the combined treatment of sorafenib and radiotherapy as an effective strategy to improve the survival rate of patients with advanced HCC.